Targeting glyco-immune checkpoints for cancer therapy-Reference-Cited by-同舟云学术

Targeting glyco-immune checkpoints for cancer therapy

Published:2021-02-08 Issue:8 Volume:21 Page:1063-1071
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Manni Michela¹,Läubli Heinz¹

Affiliation:

1. Laboratory for Cancer Immunotherapy, Department of Biomedicine, University of Basel, and Division of Medical Oncology, University Hospital Basel, Basel, Switzerland

Funder

Goldschmidt-Jacobson Foundation, the Swiss National Science Foundation

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2021.1882989

Reference114 articles.

1. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

2. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

3. A view on drug resistance in cancer

4. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

5. Biological roles of glycans

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments;Critical Reviews in Oncology/Hematology;2024-09

2. Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy;Journal for ImmunoTherapy of Cancer;2024-08

3. Generation of Monocyte-Derived Dendritic Cells with Differing Sialylated Phenotypes;Journal of Visualized Experiments;2023-10-20

4. Herpesvirus entry mediator as a potential biomarker in breast cancer compared with conventional cytotoxic T‑lymphocyte‑associated antigen 4;Biomedical Reports;2023-07-17

5. Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b;Nature Communications;2023-06-13